Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension
Overview
To assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.
Full Title of Study: “Neo Non-Randomized Hypertension Study”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: May 2012
Detailed Description
The Neo Non-Randomized Hypertension Study is a non-randomized, open-label, verification study in participants diagnosed with drug resistant hypertension, defined as medical treatment failure for hypertension defined as office cuff systolic blood pressure (SBP) ≥ 140 mmHg despite being prescribed to at least three antihypertensive medications, including a diuretic, in accordance with the AHA guidelines. Participants should remain on their prescribed anti-hypertensive medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study. All (Canadian) participants are now in long term follow-up and are required to have at least one annual visit. Parameters assessed during long-term follow-up visits: – Physical Assessment – Office Cuff Blood Pressure – Subject Medications – Serious adverse events
Interventions
- Device: BAROSTIM NEO System
- Drug: Medical Management
Arms, Groups and Cohorts
- Experimental: Device and Medical Management
- Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject’s physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
Clinical Trial Outcome Measures
Primary Measures
- To access long-term adverse events in participants implanted with the BAROSTIM NEO System.
- Time Frame: For the duration of the study, up to 10 years.
- Ascertain the type, frequency, severity and timing of long-term adverse events in participants implanted with the device, while providing a viable treatment option to participants currently implanted with CVRx’s BAROSTIM NEO System.
Participating in This Clinical Trial
Inclusion Criteria
- Actively participating in the Neo Non-Randomized Hypertension Study. – Have signed a revised approved informed consent form for continued participation in this study. Exclusion Criteria:
- Treating physician decision that the subject should not continue with therapy.
Gender Eligibility: All
Minimum Age: 21 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- CVRx, Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Hermann Haller, MD, Principal Investigator, Hannover Medical School
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.